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Ospedaliera San Giovanni Battista, Turin, Italy; and Department of Cardiac Surgery, Victoria Hospital, Blackpool, United KingdomBackground. Some controversy exists regarding the
safety of endoaortic balloon clamping in minimal access
isolated mitral valve surgery (MIMVS). The aim of this
European multicenter study was to analyze the results in
10 experienced centers and compare the outcomes with
published data.
Methods. The most recent 50 consecutive MIMVS
cases from10 European surgeons who had performed at
least 100 procedures were prospectively collected and
retrospectively analyzed. All procedures were performed
through right minithoracotomy with femoral cannulation
and endoaortic balloon occlusion. In-hospital and 30-day
outcomes were studied. Mortality and stroke rates were
compared with published median sternotomy and
MIMVS outcomes.
Results. Mean age was 63.2 ± 12.5 years, 289 (57.8%)
were male, mean logistic European system for cardiac
operative risk evaluation was 6.1 ± 6.2, and 53 (10.6%)
procedures had cardiac reoperations. Concomitant
procedures were performed in 126 (25.9%) cases. Three
patients (0.6%) required conversion to full sternotomy.
Ten patients (2.0%) necessitated endoaortic balloon
clamping conversion (8 to external clamping), andAccepted for publication April 1, 2015.
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Published by Elsevierre-exploration for bleeding was necessary in 24 (4.8%)
cases. Mean aortic cross-clamp and cardiopulmonary
bypass times were 85.6 ± 30.1 and 129.5 ± 40.2
min, respectively, and were significantly longer for
concomitant procedures (p < 0.001). There were no
aortic dissections and no deep venous thromboses.
Operative mortality (none neurologic) and major
stroke occurred in 7 (1.4%) and 4 (0.8%) patients,
respectively. These rates compared favorably with
the published literature on isolated primary mitral
valve surgery (MVS) through sternotomy or mini-
thoracotomy (mortality rates 0.2% to 11.6%, stroke rates
0.6% to 4.4%).
Conclusions. Once procedural proficiency is acquired,
endoaortic balloon clamping in MIMVS is a safe and
effective technique. Despite the fact that this patient
cohort also includes combined and redo procedures, the
observed mortality and stroke rate compared favorably
with the existing literature on primary isolated mitral
valve surgery irrespective of the approach.
(Ann Thorac Surg 2015;100:1334–9)
 2015 by The Society of Thoracic Surgeonsespite excellent operative results in mitral valveDsurgery using standard sternotomy [1], a gradual
interest has emerged to limit the invasiveness of the
procedure. As such, minimally invasive mitral valve
surgery (MIMVS) was developed in the late 1990s [2].
Since then, several methods have been used to clamp
the ascending aorta. Of these, the endoaortic balloon andexternal aortic clamp are the most frequently used
techniques.
Recently, some concerns were raised about inferior
outcomes related to the use of the endoaortic balloon in
MIMVS [3]. This information was not confirmed by pro-
spective studies but a concern about MIMVS was also
raised in a consensus paper by the International Society
for Minimally Invasive Cardiac Surgery (ISMICS ) where
an increased stroke rate was noted [4].
The aim of the current retrospective study was to analyze
the perioperative safety and outcomes associated with the
use of an endoaortic balloon. In addition, we investigated0003-4975/$36.00
http://dx.doi.org/10.1016/j.athoracsur.2015.04.003
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Study Population
Ten centers across Europe which perform MIMVS using
the endoaortic balloon (Edwards Lifesciences, Irvine, CA)
and which were beyond the learning curve (defined as an
experience >50 cases) but had performed greater than
100 cases in total (Table 1) were asked to contribute their
last 50 consecutive cases (excluding their first 50 cases) to
a database to produce a total study population of n ¼ 500.
The main reasons for preferring the endoaortic balloon
technique were absence of an extra port and direct
endoaortic cardioplegia administration, avoiding an extra
purse-string suture on the ascending aorta. All data were
extracted retrospectively from the various institutional
databases. The MIMVS was defined as any mitral repair
or replacement; concomitant atrial fibrillation surgery
and or tricuspid valve surgery were also included. Reo-
perative cardiac procedures were not excluded. Patients
who had an inadequate iliac access for endoballoon
insertion or retrograde arterial perfusion were excluded.
Other reasons for exclusion were the following: aortic
regurgitation greater than grade 2; an ascending aortic
diameter greater than 40 mm; previous right lobectomy;
extensive pleural adhesions (discovered perioperatively);
and previous aorto-bifemoral or bi-iliac grafting. Usually
emergency procedures are excluded although some cen-
ters do not take this as an exclusion criterion. Each indi-
vidual center obtained ethical committee approval for this
study but due to the retrospective and anonymous nature
of the study, individual patient consent was waived in all
centers.
Operative Technique
All patients were operated through a right minithora-
cotomy with peripheral venous and arterial cannulation,Table 1. Centers’ Experience With Minimally Invasive Mitral
Valve Surgery Prior to Case Inclusion in the Present Study
Center
Institutional Endoballoon
Experience Prior to the Study
Institutional %
of MIMVS
1 2338 91
2 51 70
3 450 99
4 450 99
5 870 12
6 360 80
7 136 85
8 345 85
9 1000 99
10 529 94
MIMVS ¼ minimally invasive mitral valve surgery (vs total cases of iso-
lated mitral valve surgery in the department).and endoaortic balloon occlusion (EndoClamp or Intra-
Clude; Edwards Lifesciences, Irvine, CA). Five centers
systematically use double (jugular and femoral) venous
cannulation, whereas the others use single venous
femoral cannulation in isolated mitral valve surgery and
double venous cannulation if tricuspid valve surgery is
associated. The operative approach for MIMVS per-
formed through a minithoracotomy has been previously
described [5]. All centers use intraoperative trans-
esophageal echocardiography monitoring. Figure 1
demonstrates the operative setup. Cardiac arrest was
obtained using intermittent cold antegrade crystalloid or
blood cardioplegia (50.0% vs 49.8%, respectively). Retro-
grade cardioplegia was not used. The nature of the car-
dioplegic solution or time intervals of reinfusion was
administered according to individual institutional pro-
tocols. Both caval veins were occluded if the right atrium
was opened.
Six centers performed atrial fibrillation ablation
surgery; 4 using cryoablation and 2 using monopolar
radiofrequency energy. The lesion set was a full left-sided
Cox-Maze lesion set; box lesion with extension to the base
of the left atrial appendage and a left isthmus lesion. Two
centers closed the left atrial appendage internally in case
of ablation.
Data Collection
Using similar templates, demographic data and preop-
erative assessment were recorded and reviewed for any
significant discrepancy. Major clinical outcome measures
included cardiopulmonary bypass time (CPB), cross-
clamp time, type of surgery, and perioperative events
such as full sternotomy conversion. Mortality and major
complications (in-hospital and up to 30 days) such as
stroke (modified Rankin Scale) [6], reoperation for
bleeding, respiratory failure, or severe infection were
collected. Echocardiographic data were recorded before,
and up to, 30 days after surgery. Definitions of these
complications were clear and accepted by all centers,
primarily based on The Society of Thoracic SurgeonsFig 1. View of the operative setup for minimally invasive mitral
valve surgery. Note the working port, the left atrial retractor shaft
(top), venting position (right from the working port), and endoscope
(under the working port).
Table 3. Surgical Procedure
Surgical Procedure
MIMVS
(500 Patients)
Replacement 131 (26.2%)
Bioprosthesis 32/131 (24.4%)
Mechanical 99/131 (75.6%)
Repair 369 (73.8%)
Commissurotomy 10/369 (2.7%)
Ring annuloplasty 363/369 (98.4%)
Chordae surgery 20/369 (5.4%)
Concomitant procedures
Tricuspid valve surgery 70/500 (14.0%)
Atrial fibrillation ablation 70/500 (14.0%)
Antegrade cardioplegia
Blood 249/500 (49.8%)
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Cscore definition. The definition of all outcome variables is
available in the Appendix.
Statistical Analysis
Quantitative continuous variables are described with
means  standard deviation and quantitative discrete
variables with absolutes and relatives frequencies. Infer-
ence statistics comparing continuous variables are made
using the Student t test and the Wilcoxon rank sum test as
appropriate. To compare discrete variables, the Pearson
c2 test was applied. Two-sided tests were utilized and a
type I error significance level of 0.05 was considered.
Early events ( 30 days post-implantation) were calcu-
lated as simple percentages (number of complications
divided by number of patients). All analyses were per-
formed with the use of R software, version 2.13.1 [7].Crystalloid 250/500 (50.0%)
MIMVS ¼ minimally invasive mitral valve surgery.Results
All participating centers had experience with MIMVS
using the endoballoon technique prior to starting this
study. The respective centers’ experience is summarized
in Table 1.
Study Population
A total of 500 patients equally distributed among the
participating centers were included. Baseline patient de-
mographic characteristics are summarized in Table 2.
Previous cardiac surgery was reported in 53 patients
(10.6%) and consisted of mitral valve surgery in 33 pa-
tients (6.6%), coronary artery bypass grafting (CABG) in
18 cases (3.6%), and aortic valve surgery in 13 cases
(2.6%). A combined procedure was performed in 126
patients.
Surgical Procedure
Perioperative details are presented in Tables 3 and 4.
Concomitant procedures (atrial fibrillation surgery or
tricuspid valve) were performed in 126 patients (140
procedures) (25.4%). The IntraClude device was used in
70.2% of cases. The CPB and cross-clamp times were
prolonged in this group versus patients without
concomitant procedures; CPB time 153.8  43.7 versus
120.8  34.8 min (p < 0.001), and cross-clamp time 98.1 Table 2. Baseline Characteristics
Characteristic
MIMVS
(500 Patients)
Age (years, mean  SD) 63.2  12.5
Male sex (%) 289 (57.8%)
Body mass index (kg/m2, mean  SD) 25.9  4.3
Preoperative atrial fibrillation 32.4%
Logistic EuroSCORE 1 (mean  SD) 6.1%  6.2%
Previous cardiac operation 10.6%
NYHA  III or IV 263/499 (52.7%)
EuroSCORE ¼ European system for cardiac operative risk evaluation;
MIMVS ¼ minimally invasive mitral valve surgery; NYHA ¼ New
York Heart Association functional class.32.7 versus 81.1  27.6 min (p < 0.001). Clamping con-
version was observed in 2.0% (10 patients; 8 patients
required a direct aortic clamping and 2 patients were
further operated on fibrillating heart) (Table 4). Surgical
conversion to full sternotomy was reported in 3 patients
(0.6%): 1 patient underwent a mitral valve repair with
unsatisfactory result and underwent a conversion to
sternotomy for valve replacement; another patient un-
derwent also an unsatisfactory mitral valve repair fol-
lowed by valve replacement during the same clamping
time but with ischemia during CPB weaning. This patient
underwent a conversion to sternotomy for additional
CABG. This patient ultimately died of severe multiple
organ failure postoperatively. The reason for the third
conversion was unclear from the retrospective analysis.
Clinical Outcomes
Thirty-day or in-hospital outcomes are summarized in
Table 5. The observed mortality rate was 1.4% (n ¼ 7). No
aortic dissection occurred and the incidence of post-
operative hemorrhage requiring re-exploration was 4.8%
(n ¼ 24 patients). Major stroke (defined as modifiedTable 4. Intraoperative Variables
Variable
MIMVS
(500 Patients)
Endoaortic occlusion 500 patients
IntraClude 351/500 (70.2%)
Endoclamp 149/500 (29.8%)
Cross-clamp time (minutes, mean  SD) 85.6  30.1
CPB time (minutes, mean  SD) 129.5  40.2
Operation time (minutes, mean  SD) 218.9  72.2
Clamping conversion 10/500 (2.0%)
Direct aortic clamping 8/10 (80.0%)
Surgical conversion to full sternotomy 3/500 (0.6%)
CPB ¼ cardiopulmonary bypass; MIMVS ¼minimally invasive mitral
valve surgery.
Table 5. Major Postoperative Outcome
30-Day Outcomes
MIMVS
(500 Patients)
Mortality 7/500 (1.4%)
Morbidity
Aortic dissection 0
Reoperation for bleeding 24/500 (4.8%)
Transfusion postoperative 159/500 (31.8%)
Deep venous thrombosis 0
TIA 3/500 (0.6%)
Permanent stroke 4/500 (0.8%)
Renal failure 13/500 (2.6%)
Groin lymphocele 7/500 (1.4%)
Myocardial infarction 5/500 (1%)
MIMVS ¼ minimally invasive mitral valve surgery; TIA ¼ transitory
ischemic attack.
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CRankin Score MRS 2) was observed in 4 patients (0.8%).
Transitory ischemic attack occurred in 3 patients (0.6%)
resulting in a total neurologic event rate of 1.4%. Renal
failure was observed in 2.6%. The incidence of a new
myocardial infarction was 1.0% (5 patients).
Echocardiographic Data
Table 6 summarizes the 30-day echocardiographic find-
ings. The cardiac function was preserved and mitral and
tricuspid valve function restored.
Literature Comparison
We compared the results to the currently available liter-
ature on isolated mitral valve surgery either minimally
invasively or through full sternotomy [1, 2, 4, 8–19].
Mortality rates reported were anywhere between 0.2 for
elective mitral valve repair [19] to 11.6% for valve
replacement [9] versus an observed mortality rate of 1.4%
in the current analysis including valve replacement,
combined and reoperative cases. The reported major
stroke rates in elective mitral valve repair were between
0.6% [19] and 4.4% [11] versus an observed major stroke
rate of 0.8% in our study population including valve
replacement, combined and reoperative procedures.Comment
Despite the fact that MIMVS has now been around for 20
years [2, 20], its penetration or adoption rate remainsTable 6. Echocardiographic Data
Echocardiographic Findings Baseline 30 Days
MR (moderate to severe – 3
or severe -4)
445/500 (89.0%) 3/396 (0.8%)
TR (moderate to severe – 3
or severe -4)
57/499 (11.4%) 8/396 (2.0%)
Ejection fraction 0.569  0.112 0.541  0.094
MR ¼ mitral valve regurgitation; TR ¼ tricuspid valve regurgitation.relatively low. Indeed, a report from The STS database
indicated that MIMVS was performed in only 20.1% of
isolated mitral valve surgery in 2008 [21]. Various reasons
may account for this. First, the transition to MIMVS re-
quires additional training, even for established practices
of mitral valve surgery. In addition, the need for different
perfusion cannulas, video-assistance, and surgical in-
struments require an investment from teams wishing to
start a MIMVS program. These factors may create a
hurdle for teams evaluating an eventual start of a MIMVS
program.
In addition, the ISMICS consensus paper of 2011 [4]
indicated longer operative times with higher incidences
of stroke, aortic dissection, phrenic nerve palsy, and groin
infection rates in order to reach a reduction in intensive
care unit and hospital stay, transfusion rate, incidence of
postoperative atrial fibrillation, and ventilation time. No
wonder that teams evaluating a potential transition to
MIMVS express reluctance to do so.
The present analysis challenges the existing literature
and studies the outcome across Europe of real world
practices in teams performing MIMVS on a regular basis.
Because adopting any new technique requires a learning
curve, we excluded these individual curves from the
present analysis. In line with the recently suggested
length of the learning curve between 35 and 75 cases
[22, 23], we defined the learning curve at 50 cases. All co-
authors estimated this to be a reasonable number,
although some subjectiveness is certainly not excluded.
We also included combined and reoperative cases.
Applying these criteria, we found very favorable
outcome data. The 30-day mortality rate was 1.4%, which
is at the lower end of reported rates for primary isolated
mitral valve surgery (0.2 to 11.6%). In addition, the major
stroke rate (modified Ranking Score 2) was only 0.8%
(compared with 0.6% to 4.4% reported so far) and no
aortic dissections occurred. These findings are in sharp
contrast with the ISMICS consensus findings [4].
While we can speculate why the results reported here
are better than results reported so far, some factors may
play a role. First, all centers participating in this analysis
made at some point a definite decision to go for MIMVS.
They were all fully experienced with mitral valve surgery
as such and made a consistent change to MIMVS. This
means that they were really dedicated to do so and per-
formed MIMVS on a regular basis, albeit introducing
some case selection in the transition period to MIMVS as
their standard technique for mitral valve surgery. We
believe it is crucially important to perform MIMVS
regularly during the learning phase in order to reach
reproducible results.
Next, the current analysis excludes the learning curve
of the various centers involved. This may have influenced
the outcome data in a favorable way. While it is not al-
ways clear in reported manuscripts if a total patient
population (including the learning curve) is considered,
one may assume so if it is not explicitly mentioned that
the learning phase is excluded. To account for this po-
tential bias, we considered “real daily life” data by also
including combined (with tricuspid or atrial fibrillation
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Csurgery) and reoperative cases. Even doing so, the
outcome data reported are excellent in comparison with
the existing literature.
Another potential influencing factor may be the type of
endo-balloon used. While most reports on MIMVS using
the endo-aortic balloon technique used the Endoclamp,
the current series used a mixture of Endoclamp and
IntraClude devices. The IntraClude has some different
features to enhance manipulation, but above all also has a
precurved zone in order to facilitate aortic arch passage
and limit balloon movement once inflated above the
sinotubular junction. It is speculated that these features
may enhance the clinical behavior of this type of endo-
balloon. However, this is unproven to date and is
currently the topic of further research.
At first glance, a mitral valve repair rate of 73.8% may
seem low to readers. However, one needs to consider that
more than 10% of the cases were reoperations and that
the patient population included both rheumatic and
degenerative valve pathology. Four of the participating
centers are located in southern Europe where the prev-
alence of rheumatic heart disease is still substantial.
While occasional attempts for valve repair are made, most
of these valves are replaced.
Limitations
The current manuscript aims to report the “real world
experience” in MIMVS using a right minithoracotomy
and endo-aortic balloon occlusion. We did not include
centers which perform robotic MIMVS using the endo-
aortic balloon. However, since the principles of patient
selection in robotic MIMVS and endo-aortic balloon oc-
clusion are similar to the population studied, we do not
anticipate any major outcome changes with the current
results.
Our patient follow-up is limited to 30 days or in-
hospital time, whichever comes last. We recognize this
may seem short but the scope of the current study was
mainly to study outcomes related to the usage of the
endo-aortic balloon. We therefore believe the study
period should suffice to detect any adverse outcomes
related to this technique.
The current manuscript reports on the usage of the
endo-aortic balloon technique. Both the Endoclamp and
IntraClude were used for aortic occlusion. The IntraClude
has incorporated some design changes (easier manipu-
lation, precurved for easier arch passage, etc) which may
have influenced the outcomes in a positive way. The
current analysis, however, was unable to account for this.
Although the aim of the study was also to compare the
current outcome data with other techniques of mitral
valve surgery, we compared our outcomes with the
existing literature rather than to set up a comparative or
controlled trial. This may influence the results somewhat
as study populations may not be fully comparable.
Nevertheless, the current study population is by no
means a selected low-risk first time population under-
going MIMVS; combined and redo procedures were
included making this a real world report on MIMVS. The
fact that we compared the current outcomes withpublished data on primary isolated mitral valve surgery
does certainly warrant against a lower risk population
studied in this paper. In fact, the opposite should be true.
Conclusions
Once procedural proficiency is acquired, endoaortic
balloon clamping in MIMVS is a safe and effective tech-
nique. Despite the fact that this patient cohort also in-
cludes combined and redo procedures, the observed
mortality (1.4%) and major stroke rate (0.8%) compared
very favorably to the existing literature on primary iso-
lated mitral valve surgery irrespective of the approach.
We believe these data strengthen the arguments to
establish and expand a MIMVS program.
Edwards Lifesciences provided statistical support. All authors are
members of the Medical advisory board on minimally invasive
cardiac surgery by Edwards Lifesciences. Edwards Lifesciences
provided reasonable travel, lodging, and honorarium for partic-
ipation by many of the authors in a medical advisory board
meeting where, as one of the agenda topics, initial concepts for
the minimally invasive manuscript were validated. Authors were
not compensated for any time spent writing or reviewing this
manuscript and claim full responsibility for the integrity of this
work.
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All complications, including death, were monitored
within 30 days after the operation
1. Postoperative blood transfusion:
Packed cells transfused after the operation were
recorded
2. Reoperation for bleeding
Any surgical reexploration (minithoracotomy or full
sternotomy) required for suspected bleeding during
the postoperative period [7].
3. TIA [transitory ischemic attack]
As proposed by the STS [Society of Thoracic Sur-
geons] database, TIA is defined as a loss of neuro-
logic function that was abrupt in onset but with
complete return of function within 24 hours.
4. Stroke
As proposed by the STS database, a postoperative
stroke is defined as any confirmed neurologic deficit
of abrupt onset caused by a disturbance in bloodsupply to the brain, that did not resolve within
24 hours.
Stroke is separated into 2 groups:
Minor: Modified Rankin score <2 at 30 days
Major: Modified Rankin score 2 at 30 days
5. Respiratory failure - Pneumonia
Severe respiratory failure is defined as intubation
>24 hours or the patient requires reintubation for
severe respiratory failure
6. Acute severe renal failure
An increase in creatinine to twice the preoperative
value or the patient receives renal replacement
therapy.
7. Myocardial infarction (MI)
Acute MI is present if 7 days from the last docu-
mented MI or evolving, if, at the time of surgery,
Q-waves or ST changes were present along with a
CK-MB >5% of total CPK [7]. If patient received
concomitant atrial fibrillation ablation, cardiac bio-
markers were not used. Only clinical signs and
electrocardiogram changes will be analyzed.
8. Peripheral ischemicevent–Majorvascularcomplication
Major vascular complications include:
U Any aortic dissection.
U Aortic rupture.
U Annulus rupture.
U Left ventricle perforation.
U New apical aneurysm/pseudoaneurysm.
U Access site or access-related vascular injury
(dissection, stenosis, perforation, rupture, arterio-
venous fistula, pseudoaneurysm, hematoma, irre-
versible nerve injury, compartment syndrome,
percutaneous closure device failure) leading to
death, life-threatening or major bleeding, visceral
ischemia or neurologic impairment.
U Distal embolization (non-cerebral) from a
vascular source requiring surgery or resulting in
amputation or irreversible end-organ damage.
U The use of unplanned endovascular or surgical
intervention associated with death, major bleeding,
visceral ischemia, or neurologic impairment.
U Any new ipsilateral lower extremity ischemia
documented by patient symptoms, physical exam,
or decreased or absent blood flow on lower ex-
tremity angiogram.
U Surgery for access site-related nerve injury OR
permanent access site-related nerve injury [8].
Aortic dissection will be recorded separately in the
database.
9. Surgical site infection
Any severe sterna infection requiring site reexplo-
ration (resternotomy if conversion occurred).
